Loading...
•
Mar 31
Sangamo Q1 2025 Earnings Report
Sangamo narrowed its losses and boosted revenue in Q1 2025 through licensing income and lower operating expenses.
Key Takeaways
Sangamo Therapeutics reported $6.4 million in revenue for Q1 2025, significantly up from the prior year due to license and collaboration fees, while cutting its net loss to $30.6 million on reduced operating costs.
Revenue rose to $6.4 million from $0.5 million in Q1 2024 due to Pfizer and Sigma-Aldrich agreements.
Net loss decreased to $30.6 million from $49.1 million year-over-year.
Non-GAAP operating expenses were $32.5 million, down from $43.6 million a year earlier.
Cash balance declined to $25.2 million, but additional capital raised post-quarter end extended runway into Q3 2025.
Sangamo
Sangamo
Sangamo Revenue by Segment
Revenue by Segment
License Fees Revenue
CapyFin.com Forward Guidance
Sangamo reiterated its 2025 guidance, with efforts focused on cost control and Fabry BLA preparation.
Positive Outlook
- Expect to submit BLA for Fabry gene therapy in Q1 2026.
- Received $18M from Lilly for capsid license in April 2025.
- Announced $23M equity raise expected to close mid-May 2025.
- Pivotal data for Fabry program expected by Q2 2025.
- Neurology-focused programs progressing toward clinical milestones.
Challenges Ahead
- Cash only sufficient into Q3 2025, with ongoing need for capital.
- No commercialization partner yet secured for Fabry program.
- Operations require additional funding to continue beyond Q3.
- Stockholder equity fell sharply to $4.9 million.
- Total assets declined nearly 15% from Q4 2024.